Search results
Results from the WOW.Com Content Network
Astellas Pharma office in Canada. Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社 ...
Astellas Institute for Regenerative Medicine is a subsidiary of Astellas Pharma located in Marlborough, Massachusetts, US, developing stem cell therapies with a focus on diseases that cause blindness. It was formed in 1994 as a company named Advanced Cell Technology, Incorporated (ACT), which was renamed to Ocata Therapeutics in November 2014. [3]
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
(Reuters) - Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing issues ...
3 Largest selling pharmaceutical products of 2015. 4 Best selling pharmaceuticals of 2013. 5 See also. ... Astellas Pharma US: Overactive bladder: Feb-2000: 2018-Nov ...
OSI Pharmaceuticals, Inc. was an American pharmaceutical company formerly based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. On Sunday, May 16, 2010 OSI agreed to be acquired by Japan-based, TSE-listed Astellas Pharma for $4.0 billion. [4] The deal was closed on June 9, 2010.
Ipragliflozin (INN, [2]: 69 trade names Suglat) is a pharmaceutical drug for treatment of type 2 diabetes. Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014, [3] and in Russia on May 22, 2019. [4] Ipragliflozin is a Sodium/glucose cotransporter 2 (SGLT2) inhibitor . [5]
Fezolinetant, sold under the brand name Veozah among others, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause. [4] [10] It is a small-molecule, orally active, selective neurokinin-3 (NK 3) receptor antagonist which is under development for the treatment of sex hormone-related disorders.